drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cell)
drug_description
An autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy given as a single IV infusion; patient T cells are engineered to express a CAR targeting CD19 to mediate cytotoxic killing and cytokine-driven clearance of malignant B cells, with expected on-target B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Relmacabtagene Autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a chimeric antigen receptor targeting CD19. Upon infusion, CAR engagement of CD19 on malignant and normal B cells activates CD3ΞΆ and costimulatory signaling, driving T-cell expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19+ cells, resulting in on-target B-cell aplasia.
drug_name
Relmacabtagene Autoleucel (Relma-cel, JWCAR029)
nct_id_drug_ref
NCT05590221